NASDAQ:OPTN - OptiNose Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $9.19 -0.28 (-2.96 %) (As of 03/24/2019 04:00 PM ET)Previous Close$9.19Today's Range$9.01 - $9.6352-Week Range$5.66 - $30.00Volume162,482 shsAverage Volume188,840 shsMarket Capitalization$379.18 millionP/E Ratio-3.43Dividend YieldN/ABeta0.65 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It also markets Onzetra Xsail (AVP-825) for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc. In addition, the company is developing XHANCE for the treatment of chronic sinusitis; OPN-300 for the treatment of Prader-Willi syndrome, a rare genetic obesity disorder, as well as autism spectrum disorder; and OPN-021 for the treatment of narcolepsy or Parkinson diseases. Further, it is involved in developing antibiotics, anticholinergics, antihistamines, mucolytics, leukotriene inhibitors, and other medication classes. OptiNose, Inc. was founded in 2010 and is headquartered in Yardley, Pennsylvania. Receive OPTN News and Ratings via Email Sign-up to receive the latest news and ratings for OPTN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OPTN Previous Symbol CUSIPN/A CIK1494650 Webwww.optinose.com Phone267-364-3500Debt Debt-to-Equity Ratio0.61 Current Ratio8.28 Quick Ratio8.01Price-To-Earnings Trailing P/E Ratio-3.43 Forward P/E Ratio-3.21 P/E GrowthN/A Sales & Book Value Annual Sales$7.07 million Price / Sales53.63 Cash FlowN/A Price / Cash FlowN/A Book Value$2.88 per share Price / Book3.19Profitability EPS (Most Recent Fiscal Year)($2.68) Net Income$-106,660,000.00 Net Margins-1,509.87% Return on Equity-77.32% Return on Assets-45.62%Miscellaneous EmployeesN/A Outstanding Shares41,260,000Market Cap$379.18 million Next Earnings Date5/13/2019 (Estimated) OptionableNot Optionable OptiNose (NASDAQ:OPTN) Frequently Asked Questions What is OptiNose's stock symbol? OptiNose trades on the NASDAQ under the ticker symbol "OPTN." How were OptiNose's earnings last quarter? OptiNose Inc (NASDAQ:OPTN) posted its quarterly earnings results on Wednesday, March, 6th. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.84) by $0.20. The firm earned $3.02 million during the quarter, compared to analysts' expectations of $2.60 million. OptiNose had a negative return on equity of 77.32% and a negative net margin of 1,509.87%. View OptiNose's Earnings History. When is OptiNose's next earnings date? OptiNose is scheduled to release their next quarterly earnings announcement on Monday, May 13th 2019. View Earnings Estimates for OptiNose. What price target have analysts set for OPTN? 4 Wall Street analysts have issued twelve-month target prices for OptiNose's shares. Their forecasts range from $25.00 to $30.00. On average, they anticipate OptiNose's stock price to reach $27.50 in the next twelve months. This suggests a possible upside of 199.2% from the stock's current price. View Analyst Price Targets for OptiNose. What is the consensus analysts' recommendation for OptiNose? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptiNose in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OptiNose. What are Wall Street analysts saying about OptiNose stock? Here are some recent quotes from research analysts about OptiNose stock: 1. According to Zacks Investment Research, "OptiNose Inc. is a specialty pharmaceutical company. It focused on the development and commercialization of products for patients treated by ear, nose and throat or ENT and allergy specialists. The company's lead product consists of XHANCE nasal polyps, XHANCE Chronic sinusitis, OPN-300, OPN- 021 and AVP-825 which are in clinical stage. OptiNose Inc. is headquartered in Pennsylvania, USA. " (2/13/2019) 2. Cantor Fitzgerald analysts commented, "We reiterate our Overweight rating and $27 price target for OPTN stock. We believe the slower than forecast ramp in Xhance launch is reflected in the current stock price. Given the reset, we believe OPTN stock presents a compelling entry point and risk/reward profile. We remain bullish on the peak sales potential for Xhance, and while we are conservative on near term sales, we believe Xhance will exceed long term expectations, and thus drive upside to OPTN stock." (2/4/2019) Has OptiNose been receiving favorable news coverage? News coverage about OPTN stock has trended neutral on Sunday, according to InfoTrie. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. OptiNose earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 3.0 out of 10, meaning that recent press coverage is unlikely to have an effect on the company's share price in the next few days. Who are some of OptiNose's key competitors? Some companies that are related to OptiNose include Puma Biotechnology (PBYI), Prestige Consumer Healthcare (PBH), Wave Life Sciences (WVE), Innoviva (INVA), Gossamer Bio (GOSS), Aimmune Therapeutics (AIMT), Clovis Oncology (CLVS), Cambrex (CBM), Phibro Animal Health (PAHC), Corcept Therapeutics (CORT), Theravance Biopharma (TBPH), TherapeuticsMD (TXMD), Apellis Pharmaceuticals (APLS), Esperion Therapeutics (ESPR) and Spectrum Pharmaceuticals (SPPI). What other stocks do shareholders of OptiNose own? Based on aggregate information from My MarketBeat watchlists, some companies that other OptiNose investors own include Clearside Biomedical (CLSD), Coherus Biosciences (CHRS), Idera Pharmaceuticals (IDRA), Proteostasis Therapeutics (PTI), Syndax Pharmaceuticals (SNDX), Viking Therapeutics (VKTX), SVB Financial Group (SIVB), Cytokinetics (CYTK), Conatus Pharmaceuticals (CNAT) and Gemphire Therapeutics (GEMP). Who are OptiNose's key executives? OptiNose's management team includes the folowing people: Mr. Peter K. Miller, CEO & Director (Age 58)Dr. Ramy A. Mahmoud M.D., M.P.H., Pres & COO (Age 54)Mr. Keith Alan Goldan, Chief Financial Officer (Age 48)Mr. Michael F. Marino, Chief Legal Officer & Corp. Sec. (Age 43)Mr. Thomas E. Gibbs, Chief Commercial Officer (Age 47) When did OptiNose IPO? (OPTN) raised $101 million in an initial public offering (IPO) on Friday, October 13th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO. Who are OptiNose's major shareholders? OptiNose's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.41%), Foresite Capital Management IV LLC (4.14%), Thrivent Financial for Lutherans (3.34%), Massachusetts Financial Services Co. MA (2.11%), Broadfin Capital LLC (1.72%) and Kornitzer Capital Management Inc. KS (1.16%). Company insiders that own OptiNose stock include Joseph C Scodari, Peter K Miller, Robert P O'neil, Sriram Venkataraman and Thomas Edward Gibbs. View Institutional Ownership Trends for OptiNose. Which major investors are selling OptiNose stock? OPTN stock was sold by a variety of institutional investors in the last quarter, including Tamarack Advisers LP, Bank of New York Mellon Corp, Millennium Management LLC and New York State Common Retirement Fund. Company insiders that have sold OptiNose company stock in the last year include Sriram Venkataraman and Thomas Edward Gibbs. View Insider Buying and Selling for OptiNose. Which major investors are buying OptiNose stock? OPTN stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Broadfin Capital LLC, Kornitzer Capital Management Inc. KS, Foresite Capital Management IV LLC, Amundi Pioneer Asset Management Inc., Prosight Management LP, Two Sigma Investments LP and Thrivent Financial for Lutherans. Company insiders that have bought OptiNose stock in the last two years include Joseph C Scodari, Peter K Miller, Robert P O'neil and Thomas Edward Gibbs. View Insider Buying and Selling for OptiNose. How do I buy shares of OptiNose? Shares of OPTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is OptiNose's stock price today? One share of OPTN stock can currently be purchased for approximately $9.19. How big of a company is OptiNose? OptiNose has a market capitalization of $379.18 million and generates $7.07 million in revenue each year. The company earns $-106,660,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. What is OptiNose's official website? The official website for OptiNose is http://www.optinose.com. How can I contact OptiNose? OptiNose's mailing address is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. The company can be reached via phone at 267-364-3500 or via email at [email protected] MarketBeat Community Rating for OptiNose (NASDAQ OPTN)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 148 (Vote Outperform)Underperform Votes: 174 (Vote Underperform)Total Votes: 322MarketBeat's community ratings are surveys of what our community members think about OptiNose and other stocks. Vote "Outperform" if you believe OPTN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPTN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/24/2019 by MarketBeat.com StaffFeatured Article: How do buyers and sellers choose a strike price?